84 filings
Page 3 of 5
8-K
c67qci
10 Jun 21
Regulation FD Disclosure
11:13am
8-K
7jvcvxl5c5k
7 Jun 21
Regulation FD Disclosure
3:13pm
8-K
or4qurw
28 May 21
Submission of Matters to a Vote of Security Holders
9:05am
8-K
38v7hi
13 May 21
Equillium Reports First Quarter 2021 Financial Results and Provides Clinical Development Update
4:13pm
8-K
arvi 6lt9bddf2m0
30 Mar 21
Equillium Announces Favorable Data From Phase 1b EQUALISE Study in Systemic Lupus Erythematosus Patients
4:52pm
8-K
7fyijz7xq3gmaty
24 Mar 21
Equillium Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development Update
4:10pm
8-K
exp8whz5
15 Mar 21
Regulation FD Disclosure
8:02am
8-K
8jgi8stg94cla
9 Mar 21
Regulation FD Disclosure
7:00am
8-K
fzb6trxpqko
12 Feb 21
Regulation FD Disclosure
3:05pm
8-K
btqjved1 f43ehj9
4 Feb 21
Equillium Announces Pricing of $30 Million Registered Direct Offering
8:10am
8-K
tjh0wwx0 du
21 Dec 20
Equillium Appoints Industry Veteran, Dolca Thomas, M.D. as Executive Vice President of
8:06am
8-K
8p8o9xv quc3h8s8
7 Dec 20
Equillium Presents Translational Data Demonstrating Impact of Itolizumab on Effector T Cell
9:24am
8-K
tvb84wgk5h0uftda8u
4 Dec 20
Regulation FD Disclosure
9:07am
8-K
gb32i1n0v 2t2
30 Nov 20
Regulation FD Disclosure
8:01am
8-K
xzpsd9x
25 Nov 20
Equillium Provides Itolizumab COVID-19 Program Update
8:01am
8-K
e6i3s5o93ccp
10 Nov 20
Equillium Reports Third Quarter 2020 Financial Results and Business Highlights
4:11pm
8-K
z465jr5q6jly5q pq01o
29 Oct 20
Equillium Receives FDA Clearance of COVID-19 IND for Phase 3 Trial
5:12pm
8-K
wchhqfmf
28 Sep 20
Departure of Directors or Certain Officers
5:00pm
8-K
zicv t17fferr9
14 Aug 20
Equillium Announces Proposed Public Offering of Common Stock
4:50pm
8-K
3qm6eyqye ivb9
12 Aug 20
Equillium Reports Second Quarter 2020 Financial Results and Recent Highlights
8:40am